Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LNCR
MCID: LNG032
MIFTS: 98

Lung Cancer (LNCR)

Categories: Cancer diseases, Genetic diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lung Cancer

About this section

MalaCards integrated aliases for Lung Cancer:

Name: Lung Cancer 57 12 74 43 73 29 6 42 3 15
Lung Carcinoma 12 29 54 6 15 17
Non-Small Cell Lung Cancer 12 74 36 29 6
Non-Small Cell Lung Carcinoma 12 15 17 71
Lung Cancer, Protection Against 57 29 6
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 57 13
Adenocarcinoma of Lung, Somatic 57 6
Lung Cancer, Susceptibility to 57 6
Lung Non-Small Cell Carcinoma 12 15
Malignant Neoplasm of Lung 43 71
Nonsmall Cell Lung Cancer 57 73
Alveolar Cell Carcinoma 73 29
Carcinoma of Lung 12 71
Lung Neoplasms 43 71
Lung Neoplasm 12 74
Nsclc 12 54
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 57
Nonsmall Cell Lung Cancer, Susceptibility to 57
Nonsmall Cell Lung Cancer, Somatic 57
Primary Malignant Neoplasm of Lung 71
Bronchioloalveolar Adenocarcinoma 71
Carcinoma, Non-Small-Cell Lung 44
Carcinoma Non-Small Cell Lung 54
Cancer, Lung, Non-Small Cell 39
Lung Cancer, Resistance to 57
Malignant Tumor of Lung 43
Adenocarcinoma of Lung 73
Lung Malignant Tumors 43
Respiratory Carcinoma 43
Lung Cancer, Somatic 57
Malignant Lung Tumor 43
Pulmonary Carcinoma 43
Pulmonary Neoplasms 43
Cancer of Bronchus 43
Cancer of the Lung 43
Lung Malignancies 43
Pulmonary Cancer 43
Neoplasm of Lung 29
Lung Carcinomas 15
Cancer of Lung 12
Lung Cancers 15
Cancer, Lung 39
Cancer Lung 54
Lncr 73

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
genes associated with susceptibility to lung cancer, e.g., faslg , fas , chrna5 , chrna3
genes associated with a protection against lung cancer, e.g., casp8 , cyp2a6
mutations in egfr (131550) are associated with altered response to treatment with tyrosine kinase inhibitors


HPO:

31
lung cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1324 DOID:3905 DOID:3908
OMIM® 57 211980
KEGG 36 H00014
NCIt 50 C2926 C4878
UMLS 71 C0007120 C0007131 C0024121 more
Sources

Summaries for Lung Cancer

About this section
MedlinePlus : 42 What is lung cancer? Lung cancer is cancer that forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women. There are two main types: small cell lung cancer and non-small cell lung cancer. These two types grow differently and are treated differently. Non-small cell lung cancer is the more common type. Who is at risk for lung cancer? Lung cancer can affect anyone, but there are certain factors that raise your risk of getting it: Smoking. This is the most important risk factor for lung cancer. Tobacco smoking causes about 9 out of 10 cases of lung cancer in men and about 8 out of 10 cases of lung cancer in women. The earlier in life you start smoking, the longer you smoke, and the more cigarettes you smoke per day, the greater your risk of lung cancer. The risk is also greater if you smoke a lot and drink alcohol every day or take beta carotene supplements. If you have quit smoking, your risk will be lower than if you had kept smoking. But you will still have a higher risk than people who never smoked. Secondhand smoke, which is the combination of smoke that comes from a cigarette and smoke breathed out by a smoker. When you inhale it, you are exposed to the same cancer-causing agents as smokers, although in smaller amounts. Family history of lung cancer Being exposed to asbestos, arsenic, chromium, beryllium, nickel, soot, or tar in the workplace Being exposed to radiation, such as from Radiation therapy to the breast or chest Radon in the home or workplace Certain imaging tests such as CT scans HIV infection Air pollution What are the symptoms of lung cancer? Sometimes lung cancer does not cause any signs or symptoms. It may be found during a chest x-ray done for another condition. If you do have symptoms, they may include Chest pain or discomfort A cough that doesn't go away or gets worse over time Trouble breathing Wheezing Blood in sputum (mucus coughed up from the lungs) Hoarseness Loss of appetite Weight loss for no known reason Fatigue Trouble swallowing Swelling in the face and/or veins in the neck How is lung cancer diagnosed? To make a diagnosis, your health care provider Will ask about your medical history and family history Will do a physical exam Will probably do imaging tests, such as a chest x-ray or chest CT scan May do lab tests, including tests of your blood and sputum May do a biopsy of the lung If you do have lung cancer, your provider will do other tests to find out how far it has spread through the lungs, lymph nodes, and the rest of the body. This is called staging. Knowing the type and stage of lung cancer you have helps your provider decide what kind of treatment you need. What are the treatments for lung cancer? For most patients with lung cancer, current treatments do not cure the cancer. Your treatment will depend on which type of lung cancer you have, how far it has spread, your overall health, and other factors. You may get more than one type of treatment. The treatments for small cell lung cancer include Surgery Chemotherapy Radiation therapy Immunotherapy Laser therapy, which uses a laser beam to kill cancer cells Endoscopic stent placement. An endoscope is a thin, tube-like instrument used to look at tissues inside the body. It may be used to put in a device called a stent. The stent helps to open an airway that has been blocked by abnormal tissue. The treatments for non-small cell lung cancer include Surgery Radiation therapy Chemotherapy Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells Immunotherapy Laser therapy Photodynamic therapy (PDT), which uses a medicine and a certain type of laser light to kill cancer cells Cryosurgery, which uses an instrument to freeze and destroy abnormal tissue Electrocautery, a treatment that uses a probe or needle heated by an electric current to destroy abnormal tissue Can lung cancer be prevented? Avoiding the risk factors may help to prevent lung cancer: Quitting smoking. If you don't smoke, don't start. Lower your exposure to hazardous substances at work Lower your exposure to radon. Radon tests can show whether your home has high levels of radon. You can buy a test kit yourself or hire a professional to do the test. NIH: National Cancer Institute

MalaCards based summary : Lung Cancer, also known as lung carcinoma, is related to lung cancer susceptibility 3 and small cell cancer of the lung, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Lung Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Non-small cell lung cancer and MicroRNAs in cancer. The drugs Ipratropium and Terbutaline have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and lymph node, and related phenotypes are lung adenocarcinoma and alveolar cell carcinoma

Disease Ontology : 12 A respiratory system cancer that is located in the lung.

MedlinePlus Genetics : 43 Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.Lung cancer is generally divided into two types, small cell lung cancer and non-small cell lung cancer, based on the size of the affected cells when viewed under a microscope. Non-small cell lung cancer accounts for 85 percent of lung cancer, while small cell lung cancer accounts for the remaining 15 percent.Small cell lung cancer grows quickly and in more than half of cases the cancer has spread beyond the lung by the time the condition is diagnosed. Small cell lung cancer often metastasizes, most commonly to the liver, brain, bones, and adrenal glands (small hormone-producing glands located on top of each kidney). After diagnosis, most people with small cell lung cancer survive for about 1 year; less than seven percent survive 5 years.Non-small cell lung cancer is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. Adenocarcinoma arises from the cells that line the small air sacs (alveoli) located throughout the lungs. Squamous cell carcinoma arises from squamous cells that line the passages leading from the windpipe (trachea) to the lungs (bronchi). Large cell carcinoma arises from epithelial cells that line the lungs. Large cell carcinoma encompasses non-small cell lung cancers that do not appear to be adenocarcinomas or squamous cell carcinomas. The 5-year survival rate for people with non-small cell lung cancer is usually between 11 and 17 percent; it can be lower or higher depending on the subtype and stage of the cancer.

OMIM® : 57 Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al., 2008). (211980) (Updated 05-Mar-2021)

CDC : 3 Cancer is a disease in which cells in the body grow out of control. When cancer starts in the lungs, it is called lung cancer. Lung cancer begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. Cancer from other organs also may spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. Lung cancers usually are grouped into two main types called small cell and non-small cell. These types of lung cancer grow differently and are treated differently. Non-small cell lung cancer is more common than small cell lung cancer.

KEGG : 36 Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer and represents a heterogeneous group of cancers, consisting mainly of squamous cell (SCC), adeno (AC) and large-cell carcinoma. Molecular mechanisms altered in NSCLC include activation of oncogenes, such as K-RAS, EGFR and EML4-ALK, and inactivation of tumorsuppressor genes, such as p53, p16INK4a, RAR-beta, and RASSF1. Point mutations within the K-RAS gene inactivate GTPase activity and the p21-RAS protein continuously transmits growth signals to the nucleus. Mutations or overexpression of EGFR leads to a proliferative advantage. EML4-ALK fusion leads to constitutive ALK activation, which causes cell proliferation, invasion, and inhibition of apoptosis. Inactivating mutation of p53 can lead to more rapid proliferation and reduced apoptosis. The protein encoded by the p16INK4a inhibits formation of CDK-cyclin-D complexes by competitive binding of CDK4 and CDK6. Loss of p16INK4a expression is a common feature of NSCLC. RAR-beta is a nuclear receptor that bears vitamin-A-dependent transcriptional activity. RASSF1A is able to form heterodimers with Nore-1, an RAS effector. Therefore loss of RASSF1A might shift the balance of RAS activity towards a growth-promoting effect.

UniProtKB/Swiss-Prot : 73 Lung cancer: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

Wikipedia : 74 Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell... more...

Sources

Related Diseases for Lung Cancer

About this section

Diseases in the Lung Cancer family:

Lung Carcinoma in Situ

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1911)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 35.2 PIK3CA NRAS MET MAP2K1 KRAS ERBB2
2 small cell cancer of the lung 34.8 PTEN PIK3CA EGFR ALK AKT1
3 adenocarcinoma 34.2 PTEN PIK3CA MET MAP2K1 KRAS ERBB2
4 lung squamous cell carcinoma 34.1 PTEN PIK3CA KRAS EGFR BRAF ALK
5 melanoma 33.7 PTEN PIK3CA NRAS MET MAP2K1 KRAS
6 endometrial cancer 33.7 PTEN PIK3CA NRAS KRAS ERBB2 EGFR
7 colorectal cancer 33.6 PTEN PPP2R1B PIK3CA NRAS MET MAP2K1
8 small cell carcinoma 33.5 PTEN KRAS ERBB2 EGFR ALK
9 breast cancer 33.4 SLC22A18 PTEN PIK3CA MET MAP2K1 KRAS
10 gastric cancer 33.4 PTEN PIK3CA NRAS MET MAP2K1 KRAS
11 neuroblastoma 33.3 PTEN PIK3CA NRAS MET MAP2K1 FASLG
12 peripheral nervous system disease 33.2 PTEN PRKN ERCC6 ERBB2 EGFR CASP8
13 skin carcinoma 33.2 PTEN PIK3CA NRAS MAP2K1 KRAS ERCC6
14 squamous cell carcinoma 33.2 PTEN PIK3CA MAP2K1 ERBB2 EGFR BRAF
15 exanthem 33.2 KRAS ERBB2 EGFR AKT1
16 bladder cancer 33.2 PTEN PIK3CA NRAS MAP2K1 KRAS ERBB2
17 ovarian cancer 33.1 PTEN PRKN PIK3CA MET MAP2K1 KRAS
18 leukemia, acute myeloid 33.1 PTEN PIK3CA NRAS MAP2K1 KRAS FASLG
19 pancreatic cancer 33.1 PTEN PIK3CA MET MAP2K1 KRAS FASLG
20 esophageal cancer 33.1 PTEN PIK3CA KRAS FASLG ERBB2 EGFR
21 glioblastoma 33.1 PTEN PIK3CA NRAS MET FASLG ERBB2
22 renal cell carcinoma, nonpapillary 33.0 PTEN PIK3CA NRAS MET FASLG EGFR
23 lung non-squamous non-small cell carcinoma 32.9 KRAS ERBB2 EGFR ALK
24 myeloma, multiple 32.9 PTEN PIK3CA NRAS KRAS ERBB2 EGFR
25 hepatocellular carcinoma 32.9 PTEN PIK3CA NRAS MET MAP2K1 KRAS
26 large cell carcinoma 32.9 KRAS ERBB2 EGFR
27 in situ carcinoma 32.8 PTEN PIK3CA ERBB2 EGFR AKT1
28 prostate cancer 32.7 PTEN PIK3CA MET MAP2K1 KRAS FASLG
29 leukemia, chronic lymphocytic 32.7 PTEN NRAS KRAS ERCC6 ERBB2 EGFR
30 squamous cell carcinoma, head and neck 32.7 PTEN PIK3CA MET MAP2K1 FASLG ERBB2
31 rhabdomyosarcoma 32.7 SLC22A18 PTEN PIK3CA NRAS MET MAP2K1
32 adenosquamous carcinoma 32.6 PTEN PIK3CA KRAS EGFR
33 myelodysplastic syndrome 32.5 PTEN NRAS KRAS IRF1 FASLG ERBB2
34 lung benign neoplasm 32.5 MET KRAS EGFR
35 skin melanoma 32.5 PTEN PIK3CA NRAS MET MAP2K1 KRAS
36 paronychia 32.4 MAP3K8 KRAS ERBB2 EGFR ALK
37 brain cancer 32.4 PTEN PIK3CA NRAS EGFR BRAF ALK
38 colon adenocarcinoma 32.4 PTEN PIK3CA KRAS FASLG ERBB2 EGFR
39 sarcoma 32.3 PIK3CA NRAS KRAS CASP8 BRAF ALK
40 lymphoma, non-hodgkin, familial 32.3 PIK3CA NRAS MAP2K1 CASP8 BRAF ALK
41 gastric adenocarcinoma 32.3 PTEN PIK3CA NRAS MAP2K1 KRAS ERBB2
42 medulloblastoma 32.3 PTEN PIK3CA NRAS MET MAP2K1 ERBB2
43 adenoma 32.3 PIK3CA KRAS BRAF AKT1
44 breast adenocarcinoma 32.3 SLC22A18 PIK3CA KRAS ERBB2 EGFR CASP8
45 kidney cancer 32.3 PTEN PIK3CA MET EGFR AKT1
46 adenoid cystic carcinoma 32.2 PTEN PIK3CA KRAS ERBB2 EGFR AKT1
47 papilloma 32.2 PTEN KRAS ERBB2 EGFR AKT1
48 large cell neuroendocrine carcinoma 32.2 ERBB2 EGFR ALK
49 glioma 32.2 PTEN PIK3CA MET ERBB2 EGFR BRAF
50 cholangiocarcinoma 32.2 PIK3CA MET KRAS ERBB2 EGFR BRAF

Graphical network of the top 20 diseases related to Lung Cancer:



Diseases related to Lung Cancer
Sources

Symptoms & Phenotypes for Lung Cancer

About this section

Human phenotypes related to Lung Cancer:

31
# Description HPO Frequency HPO Source Accession
1 lung adenocarcinoma 31 HP:0030078
2 alveolar cell carcinoma 31 HP:0006519

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Respiratory Lung:
alveolar cell carcinoma
nonsmall cell lung cancer
adenocarcinoma of lung

Neoplasia:
alveolar cell carcinoma
nonsmall cell lung cancer
adenocarcinoma of lung

Clinical features from OMIM®:

211980 (Updated 05-Mar-2021)

UMLS symptoms related to Lung Cancer:


fever, dyspnea, hemoptysis, snoring, coughing

GenomeRNAi Phenotypes related to Lung Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 74)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.88 BRAF EGFR KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.88 BRAF EGFR KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.88 KRAS
4 Decreased viability GR00106-A-0 10.88 KRAS
5 Decreased viability GR00107-A-1 10.88 MAP2K1
6 Decreased viability GR00221-A-1 10.88 EGFR KRAS PIK3CA AKT1 NRAS ALK
7 Decreased viability GR00221-A-2 10.88 KRAS PIK3CA AKT1 MAP3K8
8 Decreased viability GR00221-A-3 10.88 AKT1 ERBB2 MAP2K1 MAP3K8 NRAS
9 Decreased viability GR00221-A-4 10.88 BRAF EGFR PIK3CA AKT1 ERBB2 MAP3K8
10 Decreased viability GR00249-S 10.88 BRAF AKT1 ALK
11 Decreased viability GR00301-A 10.88 BRAF KRAS MAP3K8
12 Decreased viability GR00342-S-1 10.88 MAP3K8
13 Decreased viability GR00342-S-2 10.88 MAP3K8
14 Decreased viability GR00342-S-3 10.88 MAP3K8
15 Decreased viability GR00381-A-1 10.88 BRAF KRAS
16 Decreased viability GR00402-S-2 10.88 PIK3CA MAP3K8
17 Increased shRNA abundance (Z-score > 2) GR00366-A-10 10.62 MET
18 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.62 CYP2A6
19 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.62 MET
20 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.62 MAP3K8
21 Increased shRNA abundance (Z-score > 2) GR00366-A-119 10.62 MET
22 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.62 KRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.62 EGFR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.62 BRAF
25 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.62 PTEN
26 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.62 IRF1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.62 PTEN
28 Increased shRNA abundance (Z-score > 2) GR00366-A-160 10.62 IRF1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.62 ERBB2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-165 10.62 MAP3K8
31 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.62 ERBB2 PTEN
32 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.62 PRKN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.62 CYP2A6
34 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.62 IRF1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.62 MET
36 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.62 MET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.62 IRF1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10.62 MET
39 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.62 ERBB2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.62 EGFR
41 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.62 AKT1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.62 EGFR PTEN
43 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.62 KRAS
44 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.62 MAP3K8
45 Increased shRNA abundance (Z-score > 2) GR00366-A-27 10.62 IRF1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.62 CYP2A6 IRF1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.62 NRAS
48 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.62 ERBB2
49 Increased shRNA abundance (Z-score > 2) GR00366-A-38 10.62 MET
50 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.62 MAP3K8

MGI Mouse Phenotypes related to Lung Cancer:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 AKT1 BRAF CASP8 EGFR ERBB2 ERCC6
2 cardiovascular system MP:0005385 10.49 AKT1 BRAF CASP8 EGFR ERBB2 FASLG
3 homeostasis/metabolism MP:0005376 10.49 AKT1 ALK BRAF CASP8 EGFR ERBB2
4 growth/size/body region MP:0005378 10.47 AKT1 ALK BRAF CASP8 EGFR ERBB2
5 endocrine/exocrine gland MP:0005379 10.42 AKT1 ALK BRAF CASP8 EGFR ERBB2
6 mortality/aging MP:0010768 10.42 AKT1 ALK BRAF CASP8 EGFR ERBB2
7 integument MP:0010771 10.41 AKT1 ALK BRAF CASP8 EGFR ERBB2
8 immune system MP:0005387 10.36 AKT1 BRAF CASP8 EGFR ERCC6 FASLG
9 neoplasm MP:0002006 10.36 AKT1 ALK BRAF CASP8 EGFR ERBB2
10 embryo MP:0005380 10.32 AKT1 BRAF CASP8 EGFR ERBB2 KRAS
11 digestive/alimentary MP:0005381 10.29 BRAF EGFR ERBB2 FASLG KRAS MAP2K1
12 nervous system MP:0003631 10.28 AKT1 ALK BRAF CASP8 EGFR ERBB2
13 muscle MP:0005369 10.22 AKT1 BRAF CASP8 EGFR ERBB2 ERCC6
14 normal MP:0002873 10.22 AKT1 ALK BRAF EGFR ERBB2 FASLG
15 liver/biliary system MP:0005370 10.21 AKT1 BRAF CASP8 EGFR ERCC6 FASLG
16 craniofacial MP:0005382 10.2 BRAF EGFR ERBB2 KRAS MAP2K1 MET
17 limbs/digits/tail MP:0005371 10.13 BRAF EGFR ERBB2 ERCC6 KRAS MET
18 reproductive system MP:0005389 10 AKT1 ALK BRAF EGFR ERBB2 FASLG
19 renal/urinary system MP:0005367 9.92 BRAF CASP8 EGFR FASLG IRF1 KRAS
20 respiratory system MP:0005388 9.9 AKT1 ALK BRAF CASP8 EGFR ERBB2
21 pigmentation MP:0001186 9.85 ALK BRAF EGFR KRAS NRAS PTEN
22 skeleton MP:0005390 9.83 AKT1 ALK BRAF EGFR ERBB2 ERCC6
23 vision/eye MP:0005391 9.36 ALK BRAF EGFR ERCC6 FASLG KRAS
Sources

Drugs & Therapeutics for Lung Cancer

About this section

Drugs for Lung Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 832)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 43232 657309
2
Terbutaline Approved Phase 4 23031-25-6 5403
3
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
4
Nedaplatin Approved, Investigational Phase 4 95734-82-0
5
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
6
Caffeine Approved Phase 4 58-08-2 2519
7
Budesonide Approved Phase 4 51333-22-3 63006 5281004
8
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
9
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
10
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
11
Remifentanil Approved Phase 4 132875-61-7 60815
12
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
13
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
14
Nicotine Approved Phase 4 54-11-5 942 89594
15
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
16
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
17
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
18
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
19
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
20
Desflurane Approved Phase 4 57041-67-5 42113
21
Acetaminophen Approved Phase 4 103-90-2 1983
22
Durvalumab Approved, Investigational Phase 4 1428935-60-7
23
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
24
Vemurafenib Approved Phase 4 918504-65-1 23252090 42611257
25
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
26
Fosaprepitant Approved Phase 4 172673-20-0 219090
27
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
28
Ondansetron Approved Phase 4 99614-02-5 4595
29
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
30
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
31
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
32
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
33
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7 5280489
34
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
35
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
36 Flurbiprofen axetil Investigational Phase 4 91503-79-6
37 Vasodilator Agents Phase 4
38 acivicin Phase 4
39 Potassium Channel Blockers Phase 4
40 Anti-Infective Agents Phase 4
41 Antiviral Agents Phase 4
42 Analgesics, Non-Narcotic Phase 4
43 Analgesics Phase 4
44 Protective Agents Phase 4
45 Antioxidants Phase 4
46 Respiratory System Agents Phase 4
47 Antidotes Phase 4
48 retinol Phase 4
49 Retinol palmitate Phase 4
50 Diphosphonates Phase 4

Interventional clinical trials:

(show top 50) (show all 7466)
# Name Status NCT ID Phase Drugs
1 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
2 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
3 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
4 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (â…¢ A / â…¢ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
5 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
6 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
7 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
8 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
9 A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
10 An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation Unknown status NCT01646450 Phase 4 Icotinib
11 A Phase â…£,Open,Multicenter,Single Arm Study to Evaluate the Efficacy of the Combination Conmana With Thalidomide in Patients With NSCLC(Non-Small-Cell-Lung-Cancer) Unknown status NCT02778893 Phase 4 Conmana;Thalidomide
12 High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study Unknown status NCT02404675 Phase 4 icotinib
13 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
14 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
15 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
16 A Study to Evaluate the Efficacy and Safety of Anlotinib Plus Pemetrexed as the 1-line Treatment of Patients With Platinum Intolerant Advanced Non-squamous NSCLC, With Pemetrexed Control. Unknown status NCT03768037 Phase 4 Anlotinib plus Pemetrexed;Pemetrexed
17 An Open, Single-arm, Multi-center Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy Unknown status NCT03778853 Phase 4 Anlotinib Hydrochloride
18 A Double Blind , Randomized, Multicenter Study of Second Line Treatment of Endostar（rh Recombined Endostatin）With Single Docetaxel In NSCLC Patients Unknown status NCT00813332 Phase 4 Endostar(rh recombinant endostatin) plus Docetaxel;Placebo plus Docetaxel
19 Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
20 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
21 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
22 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
23 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
24 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
25 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
26 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
27 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
28 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
29 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
30 A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC). Completed NCT03853551 Phase 4 Osimertinib
31 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
32 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
33 Safety Study of Nivolumab for Selected Advanced Malignancies in India Completed NCT03444766 Phase 4 Nivolumab
34 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
35 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
36 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
37 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
38 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
39 A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
40 An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy Completed NCT02208843 Phase 4 Afatinib
41 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
42 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
43 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
44 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
45 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
46 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
47 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
48 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
49 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
50 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Afatinib
afatinib dimaleate
Carboplatin
Carmustine
ceritinib
Cholecalciferol
Cisplatin
CISPLATIN PWDR
crizotinib
Cyclophosphamide
docetaxel
erlotinib
Etoposide
etoposide phosphate
gefitinib
hydroxyurea
Ifosfamide
irinotecan
Irinotecan hydrochloride
Lomustine
Methotrexate
Methotrexate Sodium
Paclitaxel
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
Teniposide
Topotecan
Topotecan Hydrochloride
trametinib
Vinblastine
Vinblastine Sulfate
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: carcinoma, non-small-cell lung

Sources

Genetic Tests for Lung Cancer

About this section

Genetic tests related to Lung Cancer:

# Genetic test Affiliating Genes
1 Non-Small Cell Lung Cancer 29
2 Lung Carcinoma 29 FASLG
3 Lung Cancer, Protection Against 29
4 Alveolar Cell Carcinoma 29
5 Neoplasm of Lung 29
6 Lung Cancer 29
Sources

Anatomical Context for Lung Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Cancer:

19
Lung

MalaCards organs/tissues related to Lung Cancer:

40
Lung, Brain, Lymph Node, Bone, T Cells, Breast, Prostate
Sources

Publications for Lung Cancer

About this section

Articles related to Lung Cancer:

(show top 50) (show all 53178)
# Title Authors PMID Year
1
Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. 6 54 57
15937082 2005
2
Missense mutations of the BRAF gene in human lung adenocarcinoma. 54 6 57
12460919 2002
3
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. 61 57 6
11745231 2001
4
CYP2A6 gene deletion reduces susceptibility to lung cancer. 6 57 54
10441482 1999
5
A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. 6 57
17450141 2007
6
Lung cancer: intragenic ERBB2 kinase mutations in tumours. 57 6
15457249 2004
7
High frequency of mutations of the PIK3CA gene in human cancers. 57 6
15016963 2004
8
Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. 6 57
10217419 1999
9
C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer. 57 61
21499297 2011
10
Screening for epidermal growth factor receptor mutations in lung cancer. 57 54
19692684 2009
11
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. 47 54 61
19597153 2009
12
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. 54 61 47
18246122 2008
13
DNA methylation markers and early recurrence in stage I lung cancer. 57 54
18337602 2008
14
LKB1 modulates lung cancer differentiation and metastasis. 57 54
17676035 2007
15
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 54 57
17625570 2007
16
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 57 54
17463250 2007
17
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 54 6
15608678 2005
18
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 54 57
15329413 2004
19
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 57 54
15118073 2004
20
Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. 54 57
12802680 2003
21
BRAF and RAS mutations in human lung cancer and melanoma. 54 6
12460918 2002
22
Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. 54 57
10580025 1999
23
Association between the p21 codon 31 A1 (arg) allele and lung cancer. 54 57
8807325 1996
24
Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation. 61 42
33517297 2021
25
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 61 42
33375194 2020
26
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. 6
31666701 2019
27
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
28
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
29
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. 57
25301630 2014
30
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. 57
25301631 2014
31
Comprehensive molecular profiling of lung adenocarcinoma. 57
25079552 2014
32
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
33
Comprehensive genomic characterization of squamous cell lung cancers. 57
22960745 2012
34
A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer. 57
22883146 2012
35
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. 57
22751098 2012
36
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
37
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 6
22729223 2012
38
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 6
22729224 2012
39
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
40
Suppression of lung adenocarcinoma progression by Nkx2-1. 57
21471965 2011
41
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. 57
21430781 2011
42
Diverse somatic mutation patterns and pathway alterations in human cancers. 57
20668451 2010
43
MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). 47 54
20223231 2010
44
Identification of DOK genes as lung tumor suppressors. 57
20139980 2010
45
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. 57
19801978 2009
46
MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. 54 47
19818597 2009
47
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. 57
19692680 2009
48
miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. 47 54
19549910 2009
49
Multiple roles for Sox2 in the developing and adult mouse trachea. 57
19403656 2009
50
Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. 47 61
19273703 2009
Sources

Variations for Lung Cancer

About this section

ClinVar genetic disease variations for Lung Cancer:

6 (show top 50) (show all 614)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CYP2A6 CYP2A6*4A Deletion protective 16970
2 CASP8 NM_001228.4(CASP8):c.-937_-932del Deletion protective 7763 rs3834129 2:202097532-202097537 2:201232809-201232814
3 IRF1 NM_002198.3(IRF1):c.31T>C (p.Trp11Arg) SNV Pathogenic 14721 rs121912470 5:131825140-131825140 5:132489448-132489448
4 EGFR-AS1 NM_005228.5(EGFR):c.2303_2305delinsTCT (p.Ser768_Val769delinsIleLeu) Indel Pathogenic 638163 rs1584238193 7:55249005-55249007 7:55181312-55181314
5 BRAF NM_004333.6(BRAF):c.1405_1407del (p.Gly469del) Deletion Pathogenic 44802 rs397516890 7:140481401-140481403 7:140781601-140781603
6 EGFR NM_005228.5(EGFR):c.2127_2129del (p.Glu709_Thr710delinsAsp) Deletion Pathogenic 45220 rs397517086 7:55241679-55241681 7:55173986-55173988
7 ERBB2 NM_004448.3(ERBB2):c.2331_2339dup (p.Gly778_Pro780dup) Duplication Pathogenic 44992 rs397516981 17:37881001-37881002 17:39724748-39724749
8 EGFR-AS1 NM_005228.5(EGFR):c.2303_2304delinsTT (p.Ser768Ile) Indel Pathogenic 45252 rs397517108 7:55249005-55249006 7:55181312-55181313
9 EGFR-AS1 NM_005228.5(EGFR):c.2310_2311insGGGTTG (p.Asn771_Pro772insGlyLeu) Insertion Pathogenic 45257 rs397517111 7:55249012-55249013 7:55181319-55181320
10 EGFR-AS1 NM_005228.5(EGFR):c.2312_2314dup (p.Pro772_His773insHis) Duplication Pathogenic 45258 rs397517112 7:55249013-55249014 7:55181320-55181321
11 EGFR NM_005228.5(EGFR):c.2500G>T (p.Val834Leu) SNV Pathogenic 45279 rs397517127 7:55259442-55259442 7:55191749-55191749
12 PIK3CA</